Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A monumental cemetery built by eastern Africa's first herders near Lake Turkana, Kenya.

Hildebrand EA, Grillo KM, Sawchuk EA, Pfeiffer SK, Conyers LB, Goldstein ST, Hill AC, Janzen A, Klehm CE, Helper M, Kiura P, Ndiema E, Ngugi C, Shea JJ, Wang H.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):8942-8947. doi: 10.1073/pnas.1721975115. Epub 2018 Aug 20.

PMID:
30127016
2.

Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.

Conteh MA, Goldstein ST, Wurie HR, Gidudu J, Lisk DR, Carter RJ, Seward JF, Hampton LM, Wang D, Andersen LE, Arvay M, Schrag SJ, Dawson P, Fombah AE, Petrie CR, Feikin DR, Russell JBW, Lindblad R, Kargbo SAS, Samai M, Mahon BE.

J Infect Dis. 2018 May 18;217(suppl_1):S33-S39. doi: 10.1093/infdis/jiy061.

PMID:
29788347
3.

Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.

Jarrett OD, Seward JF, Fombah AE, Lindblad R, Jalloh MI, El-Khorazaty J, Dawson P, Burton D, Zucker J, Carr W, Bah MM, Deen GF, George PM, James F, Lisk DR, Pratt D, Russell JBW, Sandy JD, Turay P, Hamel MJ, Schrag SJ, Walker RE, Samai M, Goldstein ST.

J Infect Dis. 2018 May 18;217(suppl_1):S24-S32. doi: 10.1093/infdis/jiy042.

PMID:
29788346
4.

The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.

Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, Dawson P, Kargbo SAS, Leigh B, Bawoh M, Legardy-Williams J, Deen G, Carr W, Callis A, Lindblad R, Russell JBW, Petrie CR, Fombah AE, Kargbo B, McDonald W, Jarrett OD, Walker RE, Gargiullo P, Bash-Taqi D, Gibson L, Fofanah AB, Schuchat A; STRIVE Study Team .

J Infect Dis. 2018 May 18;217(suppl_1):S6-S15. doi: 10.1093/infdis/jiy020.

PMID:
29788345
5.

Comment: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).

Schuchat A, Seward JF, Goldstein ST, Mahon BE.

J Infect Dis. 2018 May 18;217(suppl_1):S1-S5. doi: 10.1093/infdis/jix665. No abstract available.

PMID:
29788344
6.

Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).

Fombah AE, Goldstein ST, Jarrett OD, Jalloh MI, El-Khorazaty J, Lisk DR, Legardy-Williams J, Pratt DA, George PM, Russell JBW, Schrag SJ, Dawson P, Deen GF, Carr W, Lindblad R, James F, Bah MM, Yillia JF, Sandy JD, Turay PE, Conteh MA, Slutsker L, Mahon BE, Samai M, Seward JF.

J Infect Dis. 2018 May 18;217(suppl_1):S75-S80. doi: 10.1093/infdis/jix603.

PMID:
29788342
7.

Utilizing Nurses to Staff an Ebola Vaccine Clinical Trial in Sierra Leone during the Ebola Outbreak.

Edem-Hotah J, McDonald W, Abu PM, Luman ET, Carter RJ, Koker A, Goldstein ST.

J Infect Dis. 2018 May 18;217(suppl_1):S60-S64. doi: 10.1093/infdis/jix389.

PMID:
29788340
8.

Implementing an Ebola Vaccine Study - Sierra Leone.

Widdowson MA, Schrag SJ, Carter RJ, Carr W, Legardy-Williams J, Gibson L, Lisk DR, Jalloh MI, Bash-Taqi DA, Kargbo SA, Idriss A, Deen GF, Russell JB, McDonald W, Albert AP, Basket M, Callis A, Carter VM, Ogunsanya KR, Gee J, Pinner R, Mahon BE, Goldstein ST, Seward JF, Samai M, Schuchat A.

MMWR Suppl. 2016 Jul 8;65(3):98-106. doi: 10.15585/mmwr.su6503a14.

PMID:
27387395
9.

An ectobiont-bearing foraminiferan, Bolivina pacifica, that inhabits microxic pore waters: cell-biological and paleoceanographic insights.

Bernhard JM, Goldstein ST, Bowser SS.

Environ Microbiol. 2010 Aug;12(8):2107-19. doi: 10.1111/j.1462-2920.2009.02073.x. Epub 2009 Oct 2.

PMID:
21966906
10.

Recent resurgence of mumps in the United States.

Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O'Keefe AL, Clayton J, Kightlinger LK, Dietle EG, Berg J, Kenyon CL, Goldstein ST, Stokley SK, Redd SB, Rota PA, Rota J, Bi D, Roush SW, Bridges CB, Santibanez TA, Parashar U, Bellini WJ, Seward JF.

N Engl J Med. 2008 Apr 10;358(15):1580-9. doi: 10.1056/NEJMoa0706589.

11.

Endemic hepatitis B virus infection and chronic liver disease mortality in the Republic of Palau, 1990-2002.

Vogt TM, Goldstein ST, Kuartei S.

Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1130-4. Epub 2006 Jun 12.

PMID:
16765396
12.

Phylogeny and ultrastructure of Miliammina fusca: evidence for secondary loss of calcification in a Miliolid Foraminifer.

Habura A, Goldstein ST, Parfrey LW, Bowser SS.

J Eukaryot Microbiol. 2006 May-Jun;53(3):204-10.

PMID:
16677344
13.

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents.

Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ; Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2005 Dec 23;54(RR-16):1-31. Erratum in: MMWR Morb Mortal Wkly Rep. 2006 Feb 17;55(6):158-9. MMWR Morb Mortal Wkly Rep. 2007 Dec 7;56(48):1267.

14.

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS.

Int J Epidemiol. 2005 Dec;34(6):1329-39. Epub 2005 Oct 25.

PMID:
16249217
15.

Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination.

Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ.

Pediatr Infect Dis J. 2003 Feb;22(2):157-63.

PMID:
12586980
16.

Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs.

Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, Fleenor M, Ryder PL, Margolis HS.

J Infect Dis. 2002 Mar 15;185(6):713-9. Epub 2002 Feb 28.

PMID:
11920288
17.

Toward the global elimination of hepatitis B virus transmission.

Goldstein ST, Fiore AE.

J Pediatr. 2001 Sep;139(3):343-5. No abstract available.

PMID:
11562609
18.

Factors associated with student participation in a school-based hepatitis B immunization program.

Goldstein ST, Cassidy WM, Hodgson W, Mahoney FJ.

J Sch Health. 2001 May;71(5):184-7.

PMID:
11393930
19.

An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis.

Hutin YJ, Goldstein ST, Varma JK, O'Dair JB, Mast EE, Shapiro CN, Alter MJ.

Infect Control Hosp Epidemiol. 1999 Nov;20(11):731-5.

PMID:
10580622
20.

A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team.

Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT, Goldstein ST, Gensheimer KF, Bell BP, Shapiro CN, Alter MJ, Margolis HS.

N Engl J Med. 1999 Feb 25;340(8):595-602.

21.

First reported outbreak in the United States of cryptosporidiosis associated with a recreational lake.

Kramer MH, Sorhage FE, Goldstein ST, Dalley E, Wahlquist SP, Herwaldt BL.

Clin Infect Dis. 1998 Jan;26(1):27-33.

PMID:
9455506
22.

A recombinant circumsporozoite protein vaccine against malaria.

Goldstein ST, Shapiro CN.

N Engl J Med. 1997 Jun 12;336(24):1760; author reply 1760-1. No abstract available.

PMID:
9182223
23.

Cryptosporidiosis: an outbreak associated with drinking water despite state-of-the-art water treatment.

Goldstein ST, Juranek DD, Ravenholt O, Hightower AW, Martin DG, Mesnik JL, Griffiths SD, Bryant AJ, Reich RR, Herwaldt BL.

Ann Intern Med. 1996 Mar 1;124(5):459-68. Erratum in: Ann Intern Med 1996 Jul 15;125(2):158.

PMID:
8602703

Supplemental Content

Loading ...
Support Center